BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Primary Immunodeficiency readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Primary Immunodeficie
 ncy\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06076642-11365@assetmemo.bio
DTSTAMP:20261121T004521Z
DTSTART;VALUE=DATE:20280516
DTEND;VALUE=DATE:20280517
SUMMARY:TAK-881: Phase 3 readout est. (NCT06076642)
DESCRIPTION:TAK-881\, phase 3\, Primary Immunodeficiency.\nStudy: A Study A
 bout the Long-Term Safety of TAK-881 in People With Primary Immunodeficien
 cy Diseases\nEstimated primary completion: 16 May 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/tak-881#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06076642
URL:https://assetmemo.bio/drug/tak-881#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
